Saturday, November 23, 2013 1:15:55 PM
Most investors when they see something negative posted by a questionable source about a company they are inv#sted in make some attempt to check the information against a reliable source. I highly recommend the approach and suggest you try it sometime.
Had you done so in this case, you would have found that Dr. Seymour is a HIGHLY qualified MD, not a veterinarian:
"Eugene Seymour MD, MPH
Chief Executive Officer
Dr. Seymour began practicing medic!ne in Los Angeles/ Beverly Hills in the late 1960's. In late 1981, he began treating patients with a strange new disease affecting primarily the gay population. In 1986, he was requested by the US government to establish a testing laboratory and run a large-scale surveillance pr0gram for HIV prevalence in the Hispanic population in Los Angeles"
Does THAT sound like a veterinarian?
A simple visit the the company's website would have saved you some embarssment.
And had you any least bit of concern about the company website's accuracy (even thought they would incur significant legal liabilities for any significant inaccuracies) a simple easy 30 second check of pubmed gives:
Lancet. 1993 Dec 18-25;342(8886-8887):1549.
HIV testing and blood recipients.
Frerichs RR, Seymour E.
Comment in
HIV testing and blood recipients. [Lancet. 1994]
PMID: 7902914 [PubMed - indexed for MEDLINE]
See how EASY that was?! You should really try it sometime.
PubMed.org everyone invested with biotechs should be familiar with this website.
Had you done so in this case, you would have found that Dr. Seymour is a HIGHLY qualified MD, not a veterinarian:
"Eugene Seymour MD, MPH
Chief Executive Officer
Dr. Seymour began practicing medic!ne in Los Angeles/ Beverly Hills in the late 1960's. In late 1981, he began treating patients with a strange new disease affecting primarily the gay population. In 1986, he was requested by the US government to establish a testing laboratory and run a large-scale surveillance pr0gram for HIV prevalence in the Hispanic population in Los Angeles"
Does THAT sound like a veterinarian?
A simple visit the the company's website would have saved you some embarssment.
And had you any least bit of concern about the company website's accuracy (even thought they would incur significant legal liabilities for any significant inaccuracies) a simple easy 30 second check of pubmed gives:
Lancet. 1993 Dec 18-25;342(8886-8887):1549.
HIV testing and blood recipients.
Frerichs RR, Seymour E.
Comment in
HIV testing and blood recipients. [Lancet. 1994]
PMID: 7902914 [PubMed - indexed for MEDLINE]
See how EASY that was?! You should really try it sometime.
PubMed.org everyone invested with biotechs should be familiar with this website.
Recent NNVC News
- In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides • ACCESS Newswire • 05/26/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2026 10:01:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/20/2026 08:30:33 PM
- NanoViricides Announces Closing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/19/2026 03:55:00 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/18/2026 12:45:22 PM
- Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides • ACCESS Newswire • 05/18/2026 12:30:00 PM
- NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering • ACCESS Newswire • 05/15/2026 12:35:00 PM
- NanoViricides, Inc. Has Filed its Quarterly Report - NV-387 Advancing for Phase II • ACCESS Newswire • 05/15/2026 12:00:00 PM
- Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides • ACCESS Newswire • 05/11/2026 12:30:00 PM
- NanoViricides, Inc. Announces Participation in the D. Boral Capital Global Conference • Newsfile • 05/06/2026 07:37:00 PM
- NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA • ACCESS Newswire • 05/04/2026 12:30:00 PM
- Deadly Measles Cases Accentuate the Need for a Treatment - NV-387 is Here to Help Patients and Control Spread, Says NanoViricides • ACCESS Newswire • 04/21/2026 12:30:00 PM
- Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides • ACCESS Newswire • 04/07/2026 12:30:00 PM
- Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides • ACCESS Newswire • 04/01/2026 12:30:00 PM
- NanoViricides Presenting at NIBA's 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 - Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete • ACCESS Newswire • 03/11/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:30:47 PM
- MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/12/2026 01:30:00 PM
- Measles Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides • ACCESS Newswire • 02/10/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/30/2025 09:30:18 PM
- Form DEL AM - Delaying amendment • Edgar (US Regulatory) • 12/16/2025 09:30:05 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/15/2025 09:26:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/26/2025 09:30:33 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:32:10 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 07:54:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/12/2025 04:29:54 PM
